Table 1.
Baseline characteristics and comparison between survivor and non‐survivor by status at 1 year follow‐up
| Characteristics | Survivor | Non‐survivor | P |
|---|---|---|---|
| N = 1964 | N = 44 | ||
| Male, n (%) | 822 (41.9) | 23 (52.3) | 0.17 |
| Age ≥ 70 years, n (%) | 0.74 | ||
| No | 535 (27.2) | 11 (25.0) | |
| Yes | 1429 (72.8) | 33 (75.0) | |
| HF type, n (%) | 0.50 | ||
| Right HF | 51 (2.6) | 0 (0.0) | |
| Left HF | 465 (23.7) | 12 (27.3) | |
| Total HF | 1448 (73.7) | 32 (72.7) | |
| NYHA class, n (%) | <0.01 | ||
| II | 349 (17.8) | 4 (9.1) | |
| III | 1028 (52.3) | 11 (25.0) | |
| IV | 587 (29.9) | 29 (65.9) | |
| Killip, n (%) | <0.01 | ||
| 1 | 524 (26.7) | 3 (6.8) | |
| 2 | 1019 (51.9) | 10 (22.7) | |
| 3 | 376 (19.1) | 16 (36.4) | |
| 4 | 45 (2.3) | 15 (34.1) | |
| MI history, n (%) | 139 (7.1) | 4 (9.1) | 0.61 |
| CHF history, n (%) | 1833 (93.3) | 39 (88.6) | 0.22 |
| COPD, n (%) | 230 (11.7) | 3 (6.8) | 0.32 |
| Diabetes, n (%) | 456 (23.2) | 10 (22.7) | 0.94 |
| HR, beats/min | 85.2 ± 21.5 | 88.9 ± 24.2 | 0.25 |
| SBP, mmHg | 131.2 ± 24.6 | 122.5 ± 31.2 | 0.02 |
| BMI, kg/m2 | 21.9 ± 13.8 | 20.6 ± 3.0 | 0.56 |
| CCI | 1.8 ± 1.0 | 2.3 ± 1.3 | <0.01 |
| LVEF, % | 48.7 ± 11.3 | 49.5 ± 11.2 | 0.63 |
| BUN, mmol/L | 9.4 ± 5.3 | 16.9 ± 10.2 | <0.01 |
| Creatinine, μmol/L | 106.8 ± 75.3 | 196.9 ± 151.4 | <0.01 |
| Uric acid, mmol/L | 479.5 ± 166.6 | 627.4 ± 223.3 | <0.01 |
| eGFR, mL/min/1.73 m2 | 69.4 ± 36.5 | 44.0 ± 32.3 | <0.01 |
| Cystatin, mg/L | 1.8 ± 0.9 | 2.8 ± 1.5 | <0.01 |
| Hb, g/dL | 11.5 ± 2.4 | 10.7 ± 2.9 | 0.03 |
| Na, mmol/L | 138.3 ± 4.9 | 136.1 ± 6.1 | <0.01 |
| Hs‐troponin, mg/L | 0.3 ± 2.0 | 0.4 ± 0.9 | 0.65 |
| BNP, pg/mL | 1268.4 ± 1344.9 | 2021.9 ± 1589.1 | <0.01 |
| TC, mmol/L | 3.7 ± 1.1 | 3.6 ± 1.0 | 0.36 |
| Furosemide, n (%) | 1871 (95.3) | 43 (97.7) | 0.44 |
| Torasemide, n (%) | 236 (12.0) | 4 (9.1) | 0.55 |
| Hydrochlorothiazide, n (%) | 265 (13.5) | 8 (18.2) | 0.37 |
| ACEI/ARB, n (%) | 760 (38.7) | 6 (13.6) | <0.01 |
| Hospitalization time, days | 10 ± 8 | 7 ± 11 | 0.1 |
ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CCI, Charlson Comorbidity Index; CHF, chronic heart failure; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; HF, heart failure; HR, heart rate; Hs, hypersensitivity; LVEF, left ventricular ejection fraction; MI, myocardial infarction; Na, serum sodium; NYHA, New York Heart Association; SBP, systolic blood pressure; TC, total cholesterol.
Data are presented as n (%) or mean ± SD.